Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • France(961/week)
    • Czechia(473/week)
    • Poland(348/week)
    • Germany(329/week)
    • Italy(323/week)
    • View all (3,938/week)
  • News
    • United States(407/week)
    • Manufacturing(270/week)
    • Energy(207/week)
    • Technology(312/week)
    • Professional Services(116/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Pomalidomide

Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
Apr 13, 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Mar 26, 2020
Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Dec 07, 2019
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019
Nov 06, 2019
Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Sep 26, 2019
Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed
Sep 15, 2019
New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop
Aug 16, 2019
Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15
Jul 12, 2019
Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation
Jun 02, 2019
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
  •  
  • Page 1
  • ››

Latest News

Dec 3, 2023

L'opérateur du satellite espion nord-coréen livrera ses données à l'armée

Dec 3, 2023

HII’s Ingalls Shipbuilding Christens Amphibious Assault Ship Bougainville (LHA 8)

Dec 3, 2023

Women We Admire Announces Top 50 Women Leaders of Arlington for 2023

Dec 2, 2023

Ascend atteint une étape importante en matière de réduction des GES

Dec 2, 2023

Ascend atinge marco de abatimento de gases do efeito estufa

Dec 2, 2023

India Agricultural Machinery Export Market Report 2023-2028: State-Specific Plans and Nodal Agencies Boost...

Dec 2, 2023

M.D.C. HOLDINGS' PRESENTATION AT THE RAYMOND JAMES TMT AND CONSUMER CONFERENCE TO BE WEBCAST LIVE

Dec 2, 2023

Grinding Machinery Market size to increase by USD 1.61 billion during 2023-2028, Growth in the global...

View all News

Agenda

27
February
United KingdomAshton Gate Stadium, Bristol, UK
Europe's Premier Additive Manufacturing for Aerospace, Defence and Space Conference, 27 - 28 February 2024, Ashton Gate Stadium, Bristol, UK
WIDENING THE ADOPTION OF AM IN ADVANCED MANUFACTURING The Additive Manufacturing for Aerospace, Defence & Space...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2023 EPICOS
Made by Wedia